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Abstract
Background:  Tumors and viruses have developed many mechanisms to evade the immune
system, including down-regulation of target antigens and MHC molecules. These immune escape
mechanisms may be able to be circumvented by adoptively transferring T cells engineered to
express two different T cell receptors, each specific for a different antigen or MHC restriction
molecule.
Methods: PBMC from the blood of normal healthy donors were stimulated for three days with an
antigenic peptide from cytomegalovirus (CMV) pp65. These CMV reactive cultures were
transduced with a encoding the TIL 5 T cell receptor (TCR) that mediates recognition of the
dominant epitope of the melanoma antigen MART-1. Following selection for transduced cells, the
cultures were evaluated for recognition of CMV pp65 and MART-1 expressing targets.
Results: We were able to rapidly create bifunctional T cells capable of recognizing both CMV pp65
and MART-1 using a combination of HLA-A2 tetramer staining and intracellular staining for
interferon-γ. These bifunctional T cells were sensitive to very low levels of antigen, recognize
MART-1+ tumor cells, and maintained their bifunctionality for over 40 days in culture.
Conclusion: Bifunctional T cells can be engineered by transducing short term peptide stimulated
T cell cultures. These bifunctional T cells may be more effective in treating patients with cancer or
chronic virus infections because they would reduce the possibility of disease progression due to
antigen and/or MHC loss variants.
Background
It has long been established that tumors and viruses have
multiple mechanisms for evading the immune system
including the inhibition of T cell function through the
release of inhibitory cytokines and factors [1,2], down-
regulation of MHC molecules [2,3] and the spontaneous
generation of antigen-loss variants [1-3]. In latter case,
despite the loss of a single antigen on a tumor or virus-
infected cell, there can remain functional HLA class I mol-
ecules and multiple antigens that can serve as targets for
immune destruction. Therefore, immunotherapy strate-
gies which target multiple antigens and/or multiple HLA
Published: 08 December 2004
Journal of Translational Medicine 2004, 2:42 doi:10.1186/1479-5876-2-42
Received: 28 September 2004
Accepted: 08 December 2004
This article is available from: http://www.translational-medicine.com/content/2/1/42
© 2004 Langerman et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Translational Medicine 2004, 2:42 http://www.translational-medicine.com/content/2/1/42
Page 2 of 8
(page number not for citation purposes)
class I molecules may be more effective than therapies tar-
geting single antigens presented by a single HLA class I
molecule.
We and others have shown that it is possible to use retro-
viral vectors encoding TCRs isolated from tumor- or virus-
reactive T cell clones to engineer human T cells to recog-
nize any antigen [4]. While every T cell that is transduced
to express a second TCR expresses its own TCR capable of
recognizing some antigen, it has only recently been
shown that "bifunctional" T cells capable of recognizing
two known antigens can be generated [5]. Using this tech-
nology, it may be possible to treat patients with T cells
bearing two functional T cell receptors (TCRs) with each
TCR being specific for a different tumor-associated anti-
gen (TAA) or viral antigen restricted by one or more HLA
molecule. These bifunctional T cells would retain effec-
tiveness against single antigen-loss variants or HLA loss
variants and may have improved efficacy over monospe-
cific T cells for the treatment of tumors or viruses.
In the current study, we show that it is possible to rapidly
generate T cell populations containing T cells reactive with
two defined antigens, CMV pp65 and MART-1. These T
cell cultures are highly avid for both antigens and retain
their reactivity for at least six weeks. More importantly,
this methodology could easily be adapted to closed cul-
ture systems making it more attractive for use in clinical
trials.
Methods
Tumor Cell Lines
All melanoma and renal cell carcinoma cell lines used in
this study were established from surgical specimens
obtained from cancer patients undergoing immuno-
therapy at the Surgery Branch, National Cancer Institute.
Melanoma cell lines 624 MEL (HLA-A2+, MART-1+), 624-
28 MEL (HLA-A2-, MART-1+), 1300 MEL (HLA-A2+,
MART-1+), and SK23 MEL (HLA-A2+, MART-1+) and renal
cell carcinoma cell line UOK131 (HLA-A2+, MART-1-)
were maintained complete medium (CM) which con-
sisted of RPMI 1640 medium (Life Technologies, Gaith-
ersburg, MD) supplemented with 10% heat inactivated
fetal bovine serum (Life Technologies), and penicillin
(100 U/ml)/streptomycin (100 µg/ml)/L-glutamine (2.92
mg/ml)(Life Technologies) as described [6]. The PG13 A7
retroviral producer cell line, the source of the TIL 5 TCR
retrovirus used in this study, has been described elsewhere
[7]. Retroviral production by PG13 A7 cells was carried
out using an optimized protocol described by Lamers et al
[8] in T175 flasks at 32°C in CM. T2 cells and COS A2
were maintained in CM as described [6].
T Cells
R6C12 is an HLA-A2 restricted, gp100:209–217 reactive
CTL clone that was isolated from the peripheral blood of
a melanoma patient vaccinated with the gp100:209–217
210M peptide at the Surgery Branch, National Cancer
Institute. R6C12 cells were expanded using 10 ng/ml anti-
CD3 mAb (Ortho Biotech, Raritan, NJ) and 300 IU/mL
recombinant human IL-2 (rhIL-2) (Chiron, Berkeley, CA)
in T cell medium (TCM) which consisted of RPMI 1640
supplemented with 10% pooled human AB serum (Valley
Biochemical, Winchester VA), HEPES (Life Technologies),
2-mercaptoethanol (Life Technologies), penicillin (100
U/ml)/streptomycin (100 µg/ml)/L-glutamine (2.92 mg/
ml)(Life Technologies) as described [9]. Peripheral blood
mononuclear cells (PBMC) obtained from leukapheresis
of healthy donors were used as a source of T cells for estab-
lishing CMV pp65 peptide stimulated T cell cultures and
feeders for T cell expansion were purchased from BRT Lab-
oratories (Baltimore, MD).
Peptides
All peptides used in this study were purchased from Syn-
thetic Biomolecules (San Diego, CA). Peptides used were
MART-1:27–35 (AAGIGILTV), Influenza M1:58–66
(GILGFVFTL), CMV pp65:495–503 (NLVPMVATV), or
gp100:209–217 (ITDQVPFSV). Each peptide was main-
tained as a concentrated stock (2–5 mg/ml) in 100%
DMSO (Sigma, St. Louis, MO) and diluted in the appro-
priate medium prior to immediate use.
CMV pp65 Expressing Targets
Given that it is technically difficult to obtain CMV infected
targets for immunologic assays, COS A2 cells were engi-
neered to express a mini-gene encoding the CMV
pp65:495–503 peptide epitope (COS A2 CMV). A CMV
minigene was constructed using complementary synthetic
oligonucleotide primers (sense primer: 5'-GGCCCGCG-
CAGGCAGCATGAACCTGGTGCCCATGGTGGCTACG-
GTTTAGTGA-3', anti-sense primer: 5'-
GGCCTCACTAAACCGTAGCCACCATGGGCACCAGGT-
TCATGCTGCCTGCGCG-3', Integrated DNA Technolo-
gies, Coralville, IA) that encoded the CMV pp65:495–503
peptide epitope with an ATG translation initiation codon,
a Kozak consensus sequence [10] and Not I compatible
"sticky ends" to facilitate insertion into the Not I site of
the SAMEN CMV/SRα retrovirus. Equal molar amounts of
each synthetic oligonucleotude were mixed and ligated
into the SAMEN CMV/SRa retrovirus using a rapid liga-
tion protocol and transformed into DH5α competent E.
coli cells (Life Technologies) as described [11]. Recom-
binant clones were sequenced to insure proper orienta-
tion and retroviral supernatants were produced by
cotransiently transfecting 293GP cells with plasmids
encoding the retroviral backbone and the vesicular stoma-
titis virus envelope as described [11]. COS A2 CMV cellsJournal of Translational Medicine 2004, 2:42 http://www.translational-medicine.com/content/2/1/42
Page 3 of 8
(page number not for citation purposes)
were generated by culturing COS A2 cells overnight with
retroviral supernatants supplemented with 8 µg/ml poly-
brene (Sigma).
Peptide Stimulation and Transduction of PBMC
PBMC from healthy donors were stimulated in vitro with
5 µg/ml of CMV pp65:495–503 peptide in TCM contain-
ing 300 IU/mL IL-2 for 3 days. T cell cultures were then
transduced using a modified Retronectin (TaKaRa, Otsu,
Japan) protocol with the A7 retrovirus as follows: 24-well
plates were coated with Retronectin then were preloaded
with retrovirus according to the manufacturer's instruc-
tions. 2.6 × 106 T cells were added to each well in 1.3 ml
(2 × 106 cells/ml) of A7 retroviral supernantant supple-
mented with 300 IU/ml rhIL-2 and the plates were centri-
fuged for 90 min at 1000 g. The next day the medium was
replaced with fresh A7 retroviral supernatant and the cen-
trifugation was repeated. The cells were rested for 24
hours and then transduced cells were selected in 1 mg/ml
of G418 (Research Products International, Mt. Prospect,
IL) for five days. Cultures were assayed for antigen reactiv-
ity, cyropreserved, and/or expanded for additional assays.
Transduction of T Cell Clones
T cell clone R6C12 was cultured at 2 × 106 cells/ml in TCM
supplemented with 300 IU/ml rhIL-2, and 2 µg/ml anti-
CD28 mAb (Becton, Dickenson, and Company, Franklin
Lakes, NJ) in 24 well tissue culture plates pre-coated over-
night with 10 µg of anti-CD3 mAb (Ortho Biotech,
Bridgewater, NJ) for three days prior to transduction.
Transduction of R6C12 was carried out as described above
for CMV peptide stimulated T cell cultures except 2 µg/ml
anti-CD28 mAb was added to the medium and 10 µg anti-
CD3 mAb was bound to the culture plates in addition to
Retronectin.
Antigen Recognition Assays
The antigen reactivity of each T cell culture (TIL 5 TCR
transduced and untransduced) was assayed for MART-
1:27–35 and CMV pp65:495–503 or gp100:209–217
reactivity in interferon-γ release assays. 5 × 104 T cells were
cocultured in a 1:1 ratio overnight in 0.2 ml of CM in
duplicate individual wells of a 96-well plate with a panel
of stimulators that included T2 cells loaded with 5 µg/mL
MART-1:27–35, Influenza M1:58–66, CMV pp65:495–
503, or gp100:209–217 peptide and a panel of tumor
cells. The amount of interferon-γ released was measured
by ELISA as described [6].
Intracellular Cytokine Release Assay and Tetramer 
Staining
The existence of CMV pp65:495–503/MART-1:27–35
reactive bifunctional T cells was determined by first stain-
ing T cells for intracellular interferon-γ production follow-
ing coculture with HLA-A2+  MART-1+  stimulator cells
followed by fluorescence staining with HLA-A2/CMV
pp65:495–503 tetramers. 1 × 105 T cells were cocultured
in a 1:1 ratio peptide loaded T2 cells or tumor cells for five
hours in CM supplemented with 10 µg/ml brefeldin-A.
Cells were then collected and stained with PE-conjugated
HLA-A2/CMV pp65:495503 tetramers (Beckman Coulter
Immunomics, San Diego, CA), fixed in 1% paraformalde-
hyde (Sigma), permeabilized using 0.5% saponin
(Sigma), and then stained with FITC-conjugated anti-
interferon-γ (Biosource International, Camarillo, CA).
Relative log fluorescence of 104 live cells was measured by
flow cytometry using a FACS Scan flow cytometer (BD
Biosciences, Mountain View, CA).
Results
Recognition of Peptides and Tumor Cells by TIL 5 TCR-
transduced CMV peptide stimulated T cells
Bifunctional T cells reactive with CMV and MART-1 were
engineered by first stimulating donor PBMC with CMV
pp65:495–503 peptide for three days then transducing
the T cell cultures with a retrovirus encoding a TCR spe-
cific for MART-1:27–35 presented by HLA-A2. After five
days of selection in G418, the T cells were assayed for reac-
tivity against the CMV pp65:495–503 and MART-1:27–35
antigens in interferon-γ release assays. Significant
amounts of interferon-γ were released when the TIL 5
TCR-transduced CMV peptide stimulated T cells were coc-
ultured with CMV pp65:495–503 or MART-1:27–35 pep-
tide-loaded T2 cells, COS cells engineered to express HLA-
A2 with a CMV pp65:495–503 mini-gene, or HLA-A2+
MART-1+ tumor cells (Figure 1). These cells did not release
interferon-γ when stimulated with T2 cells loaded with
Flu M1:58–66 peptide, COS A2 (MART-1- CMV-), 624-28
MEL (HLA-A2- MART-1+ CMV-), or RCC UOK131 (HLA-
A2+  MART-1- CMV-) cells. Untransduced CMV peptide
stimulated T cells only released interferon-γ when stimu-
lated with CMV pp65:495–503 peptide loaded T2 or COS
HLA-A2+ CMV+ cells. These cultures were extremely sensi-
tive to antigen stimulation since significant amounts of
interferon-γ were released when stimulated with T2 cells
loaded with 5 × 10-4 µg/mL MART-1:27–35 peptide and
<5 × 10-7 µg/mL CMV pp65:495–503 peptide (Figure 2).
These bulk cultures also continued to be reactive to both
antigens more than 40 days post transduction (Figure 3).
These results indicate that three day peptide stimulated
PBMC cultures can be activated in vitro for efficient retro-
viral transduction. Furthermore, the antigen reactivity of
these T cells is consistent with bifunctional T cells capable
of recognizing both CMV and MART-1.
Antigen Recognition by CMV-tetramer positive T cells
While the antigen reactivity of our T cell cultures was con-
sistent with us having engineered bifunctional T cells, it
was necessary to confirm that individual T cells possess
the capability to recognize both CMV pp65 and MART-1.Journal of Translational Medicine 2004, 2:42 http://www.translational-medicine.com/content/2/1/42
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To confirm that we had engineered bifunctional cells,
each T cell culture was stained with HLA-A2/CMV
pp65:495–503 tetramers for anti-CMV reactivity and with
intracellular anti-interferon-γ monoclonal antibodies fol-
lowing stimulation with HLA-A2+ MART-1+ cells for anti-
MART-1 reactivity. It should be noted that the reciprocal
experiment, staining with HLA-A2/MART-1:27–35
tetramers and intracellular anti-interferon-γ staining fol-
lowing CMV pp65:495–503 peptide stimulation could
not be performed since TIL 5 TCR expressing cells do not
bind HLA-A2/MART-1:27–35 tetramers (unpublished).
Cells that were double stained with tetramers and for
intracellular anti-interferon-γ were considered to be reac-
tive with both antigens and therefore bifunctional. As
shown in Figure 4, 2.7% of the TIL 5 TCR-transduced T
cells were double stained following stimulation with
MART-1:27–35 loaded T2 cells compared to 0.06% of the
untransduced T cells. When stimulated with CMV
pp65:495–503 peptide loaded cells, 28.35% of the TIL 5
TCR-transduced T cells were double stained. These results
are representative of multiple cultures which routinely
have approximately 10% of the CMV reactive T cells also
recognizing MART-1. These results confirm that bifunc-
tional T cells can be obtained by transducing three day
peptide stimulated PBMC cultures with retroviral vectors
encoding TCR genes.
Although the reactivity with MART-1:27–35 peptide
loaded T2 cells shown in Figure 4 confirmed that we
Recognition of peptides and tumor cells by TIL 5 TCR-trans- duced CMV-stimulated T cells Figure 1
Recognition of peptides and tumor cells by TIL 5 
TCR-transduced CMV-stimulated T cells. TIL 5 TCR-
transduced and untransduced CMV-stimulated bulk cultures 
were cocultured for 24 hours in a 1:1 ratio with T2 cells 
loaded with 5 µg/ml of peptide, COS A2 cells with or with-
out a CMV minigene, or A2+, MART-1+ tumor cells (SK23 
MEL, 624 MEL), A2-, MART-1+ tumor cells (624.28 MEL), or 
A2+, MART-1- tumor cells (UOK131 RCC). Supernatants 
were collected and the amount of interferon-γ released was 
measured using ELISA. Values are the average of triplicate 
wells.
Sensitivity of bifunctional cultures to low levels of recognized  antigens Figure 2
Sensitivity of bifunctional cultures to low levels of 
recognized antigens. TIL 5 TCR-transduced cultures were 
cocultured for 24 hours in a 1:1 ratio with T2 cells loaded 
with decreasing concentrations of peptide. Supernatants 
were collected and the amount of interferon-γ released was 
measured using ELISA. Values are the average of triplicate 
wells. Asterisk (*) indicates value was greater than maximum 
point on standard curve.
Long term maintenance of bifunctionality in culture Figure 3
Long term maintenance of bifunctionality in culture. 
TIL 5 TCR-transduced cultures were cocultured for 24 
hours in a 1:1 ratio with T2 cells pulsed with 5 µg/ml peptide 
at varying time points beyond transduction. Supernatants 
were collected and the amount of interferon-γ released was 
measured using ELISA. Values are the average of triplicate 
wells. Asterisk (*) indicates value was greater than maximum 
point on standard curve.Journal of Translational Medicine 2004, 2:42 http://www.translational-medicine.com/content/2/1/42
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successfully engineered CMV pp65 peptide stimulated
PBL-derived T cell cultures to contain bifunctional T cells,
it was important to determine if these cultures could rec-
ognize the physiologic levels of antigen presented by
tumor cells. When stimulated with HLA-A2+ MART-1+
tumor cells, 0.65% (1300 MEL) and 0.52% (SK23 MEL)
of the T cells were HLA-A2/CMV pp65 tetramer positive
and interferon-γ positive indicating that approximately
20% of the peptide reactive T cells were also tumor reac-
tive (Figure 5). Tumor cells are poor antigen presenters
relative to T2 cells because they often fail to express the
accessory molecules required for efficient T cell recogni-
tion. Furthermore, only those T cells with sufficient TIL 5
TCR expression to yield high avidity T cells are capable of
responding to the levels of processed antigen on the sur-
face of tumor cells. This explains why a smaller fraction of
bifunctional T cells are reactive with tumor cells compared
to peptide-loaded T2 cells.
MART-1 Recognition by a TIL 5 TCR-transduced gp100-
reactive T cell clone
To demonstrate that the creation of bifunctional T cells
capable of recognizing two tumor antigens was possible
using our transduction methods, T cell clone R6C12 cells
Peptide recognition by CMV tetramer+ T cells Figure 4
Peptide recognition by CMV tetramer+ T cells. TIL 5 
TCR-transduced and untransduced CMV-stimulated bulk cul-
tures were cocultured in the presence of 10 µg/ml brefeldin 
A for 5 hours in a 1:1 ratio with T2 cells pulsed with 5 µg/ml 
of peptide. Cells were then collected, stained with PE-conju-
gated HLA-A2 MHC CMV tetramer, fixed, permeabilized, 
and stained with FITC-conjugated anti-IFN-γ mAb. Samples 
were analysed using two-color flow cytometry. The percent-
age of dual positive staining cells (upper right quadrant) is as 
indicated.
Tumor cell recognition by CMV tetramer+ T cells Figure 5
Tumor cell recognition by CMV tetramer+ T cells. TIL 
5 TCR-transduced and untransduced CMV-stimulated bulk 
cultures were cocultured in the presence of 10 µg/ml brefel-
din A for 5 hours in a 1:1 ratio with A2+, MART+ tumor cells 
(SK23 MEL, 1300 MEL) or A2+, MART-1- tumor cells 
(UOK131 RCC). Cells were then collected, stained with PE-
conjugated HLA-A2 MHC CMV tetramer, fixed, permeabi-
lized, and stained with FITC-conjugated anti-IFN-γ mAb. 
Samples were analyzed using two-color flow cytometry. The 
percentage of dual positive staining cells (upper right quad-
rant) is as indicated.Journal of Translational Medicine 2004, 2:42 http://www.translational-medicine.com/content/2/1/42
Page 6 of 8
(page number not for citation purposes)
were activated with anti-CD3 and anti-CD28 mAb then
transduced to express the TIL 5 TCR. TIL 5 TCR-transduced
R6C12 cells were cocultured with gp100:209–217, Influ-
enza M1, or MART-1:27–35 peptide-loaded T2 cells. As
shown in Figure 6, TIL 5 TCR transduced R6C12 cells
released interferon-γ when stimulated with MART-1:27–
35 or gp100:209–217 loaded T2 cells, but not T2 cells
loaded with the irrelevant influenza M1 peptide. In con-
trast, untransduced R6C12 cells only released interferon-γ
when stimulated with gp100:209–217 loaded T 2 cells.
Discussion
Here we report the successful engineering of T cells that
are able to respond independently to two unrelated
known antigens via both an endogenous and a retrovi-
rally-transduced T cell receptor. These T cells were able to
respond to low concentration of peptide, and were able to
recognize antigen-positive tumor cells. By utilizing the
initial antigen response as the activation for transduction,
our 12-day protocol represents an efficient technique for
generating bifunctional T cells from donor blood, and
theoretically can be applied to any tumor or viral antigen
in the context of one or more MHC restricting elements.
Many previous efforts at creating TCR transductants used
non-specific activation of bulk or clonal populations
[7,8,12] or, for the creation of bifunctional T cells, specific
activation of semi-clonal populations with peptide-
loaded autologous PBMC [5]. Non-specific T cell activa-
tion fails to expand T cell populations with known reactiv-
ity hence making it virtually impossible engineer T cells
reactive with two know antigens. Engineering clonal or
semi-clonal populations of T cells will create T cells reac-
tive with two known antigens [5]. However, this process
necessitates the establishment of antigen reactive T cell
clones or long term T cell cultures prior to transduction.
Although technically feasible, the creation of bifunctional
T cells from T cell clones (this study) or long term T cell
cultures [5] is time consuming and in our experience has
a comparatively low yield of bifunctional cells. Further-
more, it is likely that the reactivity and therapeutic efficacy
of T cells are diminished with extended culturing (13).
Therefore, any method capable of rapidly producing
bifunctional T cells will be better suited to clinical
applications.
In contrast to using anti-CD3 mAb, in vitro stimulation
with antigenic peptides will preferentially activate antigen
reactive T cells to expand. These proliferating antigen reac-
tive T cells can be transduced to express a second TCR.
Based on our tetramer analysis, only 0.7% of the unstim-
ulated donor PBL stained with the CMV tetramer (data
not shown), compared to 44.6% of our peptide stimu-
lated populations (data not shown). This profound
expansion allowed for more efficient transduction, and
2.7% of the resulting culture was measurably bifunctional
(figure 4). As retroviral transduction and in vitro selection
for transduced T cells becomes more efficient, the fre-
quency of bifunctional T cells in these cultures will
increase to the point where it is feasible to treat patients.
The combination tumor/viral bifunctional cells we have
generated here may have novel uses in immunotherapy,
such as bypassing tumor- or viral-induced T cell unre-
sponsiveness. Fossati and colleagues demonstrated that
naïve bifunctional T cells "preactivated" via one TCR prior
to adoptive transfer would then mediate cytotoxicity via
the second TCR [14]. Animal and in vitro studies have
shown that peripherally-induced tolerance can be
reversed, resulting in regained T cell responsiveness
[15,16]. It may be possible to reactivate tolerized T cells in
vitro or in vivo by activating a second T cell receptor specific
for a non-tolerized antigen [16,17]. In addition, viral anti-
gens such as those associated with influenza, trigger alter-
nate T cell activation pathways [18] and have been shown
to elicit a strong T cell immune response [19]. Redirecting
the vigorous anti-viral T cells which have not been
exposed to the immunologic tolerance associated with
most tumor-reactive T cells may be effective in eradicating
tumor burden.
The substantial proliferation in response to strong immu-
nogens such as viral antigens can also be used to improve
the localization of T cells that also have anti-tumor
activity. Using murine bifunctional T cells created by ret-
Peptide recognition by TIL 5 TCR-transduced gp100-reactive  T cell clone Figure 6
Peptide recognition by TIL 5 TCR-transduced gp100-
reactive T cell clone. TIL 5 TCR-transduced and untrans-
duced R6C12 cells were cocultured for 24 hours in a 1:1 
ratio with T2 cells loaded with 5 µg/ml of peptide. Superna-
tants were collected and the amount of interferon-γ released 
was measured using ELISA. Values are the average of dupli-
cate wells.Journal of Translational Medicine 2004, 2:42 http://www.translational-medicine.com/content/2/1/42
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roviral transfer of a chimeric immunoglobulin receptor
specific for an ovarian cancer-associated tumor antigen to
alloreactive T cells, Kershaw and colleagues were able to
demonstrate  in vivo expansion in response to
alloimmunization and demonstrated anti-tumor activity
[20]. It is possible that tumor/viral bifunctional cells
would also behave in this way, and we are currently work-
ing on murine models with human/mouse chimeric TCRs
to test this hypothesis.
In addition, some current immunotherapy protocols for
the treatment of metastatic melanoma involve immun-
odepletion prior to adoptive cell transfer [21]. Such pro-
tocols are similar to solid organ and stem cell
transplantation in that the patients are temporarily immu-
nosuppressed and at risk for reactivation of latent viruses
such as CMV and Epstein-Barr virus. Tumor/viral
bifunctional T cells may be particularly useful in this set-
ting, where the anti-viral activity may help treat reactiva-
tion, and the reactivation of the virus may further boost
the anti-tumor activity of the T cells by inducing addi-
tional stimulation of the bifunctional cells.
Another consideration to bear in mind with the creation
of bifunctional T cells is alternate pairing of the alpha and
beta chains resulting in the combination of novel T cell
receptors within a bifunctional cell. These T cells could
have undesirable autoimmune properties. This could be
circumvented by identifying T cells within a bifunctional
population that have maximal expression of both the
endogenous and introduced TCRs, indicating minimal
cross-pairing of chains [6]. Screening for these T cells and
selectively expanding them would reduce the risk of unto-
ward autospecificity.
In our experiences, it has been difficult to transduce PBL-
derived T cells from normal donors that are stimulated
with antigenic peptides derived from self-antigens (data
not shown). This is likely due to the low precursor fre-
quency and/or the state of immunologic tolerance of T
cells reactive with antigens such as gp100 or tyrosinase
[20,22,23]. These limitations do not preclude generating
T cells capable of recognizing two different tumor anti-
gens, for we have demonstrated here that a T cell clone
reactive with gp100:209–217 can be engineered to also
recognize MART-1. However, transducing T cell clones is
more time consuming since it is first necessary to isolate
the T cells clones prior to transduction. There are two
potential strategies for overcoming the limitations of
transducing T cells with low precursor frequencies or that
are immunologically tolerant. First, is transducing actively
expanding tumor infiltrating lymphocyte cultures which
contain tumor antigen-reactive T cells [24]. Second,
patients vaccinated against tumor associated self antigens
often have increased frequencies of antigen reactive T cells
in their peripheral blood [23], and these T cells may lend
themselves to activation and expansion in vitro to enable
efficient retroviral transduction.
Conclusion
The approach for generating bifunctional T cells we
describe in this study may be feasible for viral infections
and malignancies and may represent a powerful approach
for those patients that otherwise would fail immuno-
therapy due to the accumulation antigen- or MHC-loss
variants.
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